01921cam a2200265Ii 450000500170000000800410001702000180005802000180007602400350009403501120012904000550024104100080029606000110030424500940031526000220040930000240043149000220045550509950047765000270147265000330149965000280153270000300156070000290159077600360161920180315112543.0180315s2017    sz a    rb    000 0 eng d  z9783319404004  a97833194039917 a10.1007/978-3-319-40400-42doi  a(OCoLC)961910126z(OCoLC)961931795z(OCoLC)962017915z(OCoLC)962065441z(OCoLC)974649704z(OCoLC)1005793172  aCO-BoUCMbspaerdacSandra PalaciodSandra Palacio0 aeng  aQV 77100aPharmacovigilancebcritique and ways forwardcI. Ralph Edwards, Marie Lindquist, editores  aSuizabAdisc2017  axxxi, 205 páginas0 aMedicine, General0 a1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes -- 'Silent Factors' Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of 'Health' -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.17aFarmacoepidemiología27aDrogas xEfectos secundarios27aInteracción de drogas1 aEdwards, I. Ralpheeditor1 aLindquist, Marieeeditor08iPrinted edition:z9783319403991